Sentence: In two trials , an anti-EGFR antibody ( panitumumab or cetuximab ) reduced median survival when added to bevacizumab in previously untreated patients .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['panitumumab', 'bevacizumab'], 'is_context_needed': False}, {'class': 'NEG', 'spans': [1, 2], 'is_context_needed': False}]